{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974015",
  "id": "02974015",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250729",
  "time": "1705",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8k2hzy4j914.pdf",
  "summary": "### **Form 604 Summary \u2013 Change in Substantial Holding**  \n**Company:** Chimeric Therapeutics Limited (ASX: CHM)  \n\n#### **Key Points:**  \n- **Substantial Holder:** Paul Hopper  \n- **Change in Voting Power:**  \n  - **Previous Holding (28 May 2025):** 204,994,574 shares (10.2%)  \n  - **Current Holding (25 July 2025):** 204,994,574 shares (**6.3%** *[implies dilution from capital raising]*).  \n- **Breakdown of Current Holdings:**  \n  - Directly held: 21,232,142 shares  \n  - Via associates (Deborah Coleman, Moreglade Pty Ltd, Kilinwata Investments Pty Ltd): 183,762,432 shares.  \n- **Change Trigger:** Dilution due to issuance of new shares (*implied from voting power drop, though no explicit capital raise detail provided*).  \n\n#### **Material Implications:**  \n- Significant dilution (voting power reduction from 10.2% to 6.3%) suggests a capital raising event not fully detailed in this notice.  \n- No change in total shares held by Hopper\u2014confirms passive dilution.  \n\n**Action:** Monitor for subsequent capital raise announcements or Appendix 3B filings to confirm details.  \n\n*(Note: No direct capital raising terms or pricing disclosed here.)*",
  "usage": {
    "prompt_tokens": 1809,
    "completion_tokens": 293,
    "total_tokens": 2102,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T08:03:39.210516"
}